Gastric atrophy, intestinal metaplasia or dysplasia: reviewing the report before Shanghai care
gastric atrophy metaplasia dysplasia report review Shanghai
When an endoscopy report says “atrophy”, “intestinal metaplasia” or “dysplasia”, the important question is your own risk and next step. A Shanghai gastroenterology team can combine biopsy location, pathology and endoscopy images to decide whether surveillance, more sampling or endoscopic treatment is appropriate. eastmedgo can prepare the record, find the right hospital and coordinate results.
By eastmedgo editorial ·
On this page
The terms describe different findings
Atrophy involves loss of normal stomach glands; intestinal metaplasia means that cells resembling intestinal lining have replaced part of the stomach lining. These changes can be associated with increased stomach cancer risk, but they do not mean that cancer is inevitable. Dysplasia describes abnormal neoplastic epithelial changes without stromal invasion and is graded; it needs a different level of attention from uncomplicated inflammation. Ask for the exact wording and grade, rather than relying on a verbal description such as 'a precancerous stomach'.
The location of the biopsies helps interpret risk
A biopsy result represents sampled tissue, not a complete map of the stomach. Bring the full endoscopy report and images, pathology report and labels identifying where samples were taken. Changes limited to the antrum can have a different implication from changes involving both the antrum and the body of the stomach. If locations were not documented clearly, the team may need to clarify the sampling before recommending surveillance. Ask whether the examination adequately assessed the mucosa and whether a visible abnormal area was investigated separately.
Sources and references: [2] [3]
Dysplasia needs a specific assessment pathway
When a report says low-grade or high-grade dysplasia, or uses an uncertain phrase such as 'indefinite for dysplasia', expert gastrointestinal pathology review can be important. The next question is whether a visible lesion explains the finding. A high-quality repeat examination may be needed when dysplasia has no clearly identified lesion, while a visible abnormality requires assessment of its extent and appropriate management. Do not assume that a routine annual check is the right response to every dysplasia report. Obtain the slides or tissue blocks if the reviewing centre requests them.
Sources and references: [3]
H. pylori and family history belong in the same review
Helicobacter pylori infection is a recognised risk factor, and management of infection is part of care for gastric precancerous conditions. Bring previous test results, eradication treatment details and any confirmation testing, rather than assuming that an old prescription proves the infection has cleared. A first-degree relative with stomach cancer and the pattern of the tissue changes can influence the discussion. Treating infection does not replace assessment of dysplasia or a suspicious visible lesion. The clinician should decide how testing and treatment fit into the overall plan.
Avoid a one-interval-fits-everyone schedule
The 2025 MAPS III guideline distinguishes extensive or advanced changes from limited changes without additional risk factors. Some patients need endoscopic surveillance; others may not need a routine surveillance programme on the basis of that finding alone. This is a risk-based framework, not an instruction that every person should undergo yearly gastroscopy. It is also a European guideline rather than a booking rule for China. Ask the treating specialist to explain the proposed interval, what features justify it and what new information would bring a review forward.
Sources and references: [2]
What Renji's gastroenterology scope contributes
“Gastric atrophy”, “intestinal metaplasia” and “dysplasia” do not mean the same risk or call for the same response. The gastroenterology service at Renji Hospital, Shanghai Jiao Tong University School of Medicine works with gastric precancerous conditions, early cancer and endoscopic treatment. A Shanghai review of endoscopy images, biopsy locations and pathology can clarify whether a closer look, more sampling, surveillance or treatment of a visible lesion is appropriate. The result should fit your actual risk, not a one-size-fits-all interval. Read our Gastric precancerous conditions guide, then let eastmedgo help organise the next step.
Sources and references: [4]
Price the assessment that is actually proposed
Separate the cost of consultation, pathology review, gastroscopy, sedation or anaesthesia, biopsies and H. pylori testing. If a lesion might require treatment, request a separate estimate for that decision rather than assuming diagnostic endoscopy includes resection. Explain your medicines, allergies, previous sedation problems and major illnesses so the team can plan preparation appropriately. Do not independently stop prescribed medicines based on a generic travel checklist. Clarify who will explain the results, how long the assessment stages may take and whether another visit could be required.
Keep the written risk explanation with the results
Before returning home, obtain the final pathology interpretation, the biopsy locations, any treatment report and a follow-up plan that names the reason for the proposed interval. Share these with the clinician who will provide continuing care; an isolated label such as 'metaplasia' loses much of the useful context. New vomiting of blood or black, tarry stools needs urgent local assessment rather than waiting for an overseas appointment. eastmedgo can organise the records needed for setting surveillance from biopsy locations, endoscopy images and pathology, match you with Shanghai specialists and coordinate bilingual communication and return-home handover. To discuss your records and the next step, contact eastmedgo.
Common questions
Does intestinal metaplasia mean I already have stomach cancer?
No. It describes a change in the lining that can be associated with cancer risk. Interpretation depends on its extent, accompanying findings and personal risk factors; it is not a diagnosis of cancer by itself.
Should everyone with gastric atrophy have a gastroscopy every year?
No universal annual schedule follows from that term alone. The severity and extent of changes, family history, infection and other pathology findings help determine whether surveillance is needed and how it should be timed. Bring the original pathology with biopsy locations and endoscopy images so follow-up timing can reflect the extent of change.
Sources and references: [2]
Can I finish H. pylori treatment and ignore a dysplasia result?
No. Infection management and assessment of dysplasia answer different questions. Make sure the pathology result is reviewed and that any need for further endoscopic assessment is addressed, even while infection treatment is being arranged.